Overview

Study of Enfuvirtide in HIV-Positive Subjects

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.

Phase:

Phase 1

Details

Lead Sponsor:

Trimeris

Collaborator:

Hoffmann-La Roche

Treatments:

Enfuvirtide